Third-line therapy for advanced non-small-cell lung cancer patients: Feasible drugs for feasible patients

Medical Oncology

Volumn 28, Issue SUPPL. 1, 2011, Pages

  Song, Zhengbo ^a   Yu, Yongfeng ^a   Chen, Zhiwei ^a   Lu, Shun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Non small cell lung cancer; Overall survival; Progression free survival; Third line treatment

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; DRUG TREATMENT FAILURE; FEASIBILITY STUDY; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY;

EID: 84655174963     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9753-3     Document Type: Article

References (22)

1. A Jemal 2009 Cancer statistics 2009 CA Cancer J Clin 59 225 249
2. Pass H, et al. Lung cancer: principles and practice. Philadelphia: Lipponcott Williams & Wilkins; 2000.
3. NJ Petrelli 2009 Clinical cancer advances 2009:major research advances in cancer treatment, prevention, and screening-A reports from the american society of clinical oncology J Clin Oncol 27 6052 6069
4. Non-Small Cell Lung Cancer Collaborative Group 1995 Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials Br Med J 311 899 909
5. Non-Small Cell Lung Cancer Collaborative Group 2008 Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized clinical trials J Clin Oncol 26 4617 4625
6. JH Schiller 2002 Eastern cooperative oncology group: comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 92 98 (Pubitemid 34438899)
7. FA Shepherd 2000 Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2095 2103 (Pubitemid 30324363)
8. FV Fossella 2000 Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group J Clin Oncol 18 2354 2362 (Pubitemid 30415821)
9. N Hanna 2004 Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy J Clin Oncol 22 1589 1597 (Pubitemid 41079796)
10. N Thatcher 2005 Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 1527 1537 (Pubitemid 41540110)
11. FA Shepherd 2005 Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 123 132 (Pubitemid 41058344)
12. JM Sun 2008 Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer Jpn J Clin Oncol 39 27 32
13. G Nicolas 2009 Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice J Thorac Oncol. 4 1544 1549
14. P Therasse 2000 New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216
15. Trotti A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176-181. (Pubitemid 36962641)
16. GA Christopher 2009 American society of clinical oncology clinical practice. Guideline update on chemotherapy for stage IV non-small-cell lung cancer J Clin Oncol 27 6251 6266
17. I Yoshino 2002 A time trend of profile and surgical results in 1123 patients with non-small cell lung cancer Surgery 131 S242 S248
18. E Massarelli 2003 A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer Lung Cancer 39 55 61 (Pubitemid 36020295)
19. MD Maio 2009 Meta-Analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer J Clin Oncol 27 1836 1843
20. HS Kim 2010 A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer Lung Cancer 70 71 76
21. Smit EF, et al. A radomized phase II Study of pemetrexed (P) versus pemetrexed-carboplatin (PC) as second-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC)-NVALT7. J Clin Oncol. 2008; 26:436 s, (abstract 8050).
22. YM Chen 2006 Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy J Thorac Oncol 1 545 550